Business Description
Celldex Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US15117B2025
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 336.4 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 49.98 | |||||
Beneish M-Score | 2.38 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.2 | |||||
3-Year EBITDA Growth Rate | -23.1 | |||||
3-Year EPS without NRI Growth Rate | -21.3 | |||||
3-Year FCF Growth Rate | -16.7 | |||||
3-Year Book Growth Rate | 13.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -7.55 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -18.03 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.25 | |||||
9-Day RSI | 61.25 | |||||
14-Day RSI | 60.53 | |||||
6-1 Month Momentum % | -31.02 | |||||
12-1 Month Momentum % | 12.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 29.36 | |||||
Quick Ratio | 29.36 | |||||
Cash Ratio | 29.01 | |||||
Days Sales Outstanding | 63.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 | |||||
Shareholder Yield % | -15.62 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1966.89 | |||||
Net Margin % | -1809.4 | |||||
FCF Margin % | -1480.19 | |||||
ROE % | -28.82 | |||||
ROA % | -27.22 | |||||
ROIC % | -419.65 | |||||
3-Year ROIIC % | 2958.1 | |||||
ROC (Joel Greenblatt) % | -2444.7 | |||||
ROCE % | -31.03 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 273.95 | |||||
PB Ratio | 3.39 | |||||
Price-to-Tangible-Book | 3.51 | |||||
EV-to-EBIT | -12 | |||||
EV-to-Forward-EBIT | -7.84 | |||||
EV-to-EBITDA | -12.24 | |||||
EV-to-Forward-EBITDA | -7.84 | |||||
EV-to-Revenue | 236.12 | |||||
EV-to-Forward-Revenue | 363.02 | |||||
EV-to-FCF | -15.95 | |||||
Price-to-Median-PS-Value | 2.97 | |||||
Price-to-Net-Current-Asset-Value | 3.54 | |||||
Price-to-Net-Cash | 3.58 | |||||
Earnings Yield (Greenblatt) % | -8.33 | |||||
FCF Yield % | -4.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Celldex Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 7.674 | ||
EPS (TTM) (€) | -2.546 | ||
Beta | 1.45 | ||
Volatility % | 72.85 | ||
14-Day RSI | 60.53 | ||
14-Day ATR (€) | 0.901076 | ||
20-Day SMA (€) | 34.78 | ||
12-1 Month Momentum % | 12.03 | ||
52-Week Range (€) | 21.2 - 47.8 | ||
Shares Outstanding (Mil) | 66.29 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Celldex Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Celldex Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Celldex Therapeutics Inc Frequently Asked Questions
What is Celldex Therapeutics Inc(FRA:TCE2)'s stock price today?
When is next earnings date of Celldex Therapeutics Inc(FRA:TCE2)?
Does Celldex Therapeutics Inc(FRA:TCE2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |